{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for nonoxynol root_codes_LOINC in LOINC (approximate match)
Status:
US Approved Rx
(2013)
First approved in 2007
Class:
PROTEIN
Status:
US Approved Rx
(2006)
Source:
BLA125151
(2006)
Source URL:
First approved in 2006
Source:
BLA125151
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2004)
Source:
BLA021765
(2004)
Source URL:
First approved in 1997
Source:
BLA020378
Source URL:
Class:
PROTEIN
Status:
US Approved Rx
(2010)
Source:
NDA022432
(2010)
Source URL:
First approved in 1950
Source:
ACTHAR by SANOFI AVENTIS US
Source URL:
Class:
PROTEIN
Conditions:
Corticotropin is a polypeptide hormone produced and secreted by the pituitary gland. Corticotropin acts through the stimulation of cell surface the adrenocorticotropic hormone (ACTH) receptors, which are primarily located on the adrenocortical cells. Corticotropin stimulates the cortex of the adrenal gland and boosts the synthesis of corticosteroids, mainly glucocorticoids but also sex steroids (androgens).
Corticotropin is indicated as monotherapy for the treatment of exacerbations of multiple sclerosis in adults and infantile spasms in infants and children under 2 years of age. Controlled clinical trials have shown Corticotropin to be effective in speeding the resolution of acute exacerbations of multiple sclerosis. However, there is no evidence that it affects the ultimate outcome or natural history of the disease. The mechanism of action of Corticotropin in the treatment of infantile spasms is unknown.
Status:
US Approved Rx
(2013)
Source:
ANDA200219
(2013)
Source URL:
First marketed in 1928
Class:
PROTEIN
Targets:
Conditions:
More than a century ago, Sir Henry Dale demonstrated that a component of the pituitary causes contractions of the mammalian uterus, hence his coining the term “oxytocic,” derived from the Greek for “quick birth,” for its activity. The discovery that a component of the pituitary causes milk secretion followed within a few years. By 1930, oxytocin was separated from vasopressin into pitocin and pitressin, respectively, at Parke Davis and made available for research. That a single peptide was responsible for these uterine and mammary actions was definitively confirmed upon the sequencing and synthesis of the peptide, 9 amino acids in length. Vincent du Vigneaud was awarded a Nobel Prize for this work.
Oxytocin is indicated for the initiation or improvement of uterine contractions, where this is desirable and considered suitable for reasons of fetal or maternal concern, in order to achieve vaginal delivery. Oxytocin is indicated to produce uterine contractions during the third stage of labor and to control postpartum bleeding or hemorrhage. Uterine motility depends on the formation of the contractile protein actomyosin under the influence of the Ca2+- dependent phosphorylating enzyme myosin light-chain kinase. Oxytocin promotes contractions by increasing the intracellular Ca2+. Oxytocin has specific receptors in the myometrium and the receptor concentration increases greatly during pregnancy, reaching a maximum in early labor at term. The Oxytocin receptor is a typical class I G protein-coupled receptor that is primarily coupled via G(q) proteins to phospholipase C-beta. The high-affinity receptor state requires both Mg(2+) and cholesterol, which probably function as allosteric modulators. The agonist-binding region of the receptor has been characterized by mutagenesis and molecular modeling and is different from the antagonist binding site. The function and physiological regulation of the Oxytocin system is strongly steroid dependent.
Status:
Investigational
Source:
NCT04619602: Phase 1 Interventional Suspended Bronchopulmonary Dysplasia
(2025)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03673657: Phase 2 Interventional Completed Local Advanced Non-small Cell Lung Cancer
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01373450: Phase 1 Interventional Completed Type 2 Diabetes Mellitus
(2011)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03188887: Phase 3 Interventional Completed IgA Nephropathy
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT01309425: Phase 1 Interventional Completed Healthy Volunteer
(2011)
Source URL:
Class:
PROTEIN